Journal of Clinical Immunology and Allergy

Para Neoplastic Antigens as Biomarkers for Early Detection and Prediction of Recurrence of Ovarian Cancer

Pneumoconiosis Routine disease monitoring of ovarian cancer patients is generally recommended by gynecologic oncologists for women from high-risk families and for ovarian cancer patients during after the completion of primary surgery and first-line chemotherapeutic treatments. The recurrence is determined by measuring the level of serum CA125, one of the most extensively used tumor biomarkers in standard clinical practice for disease surveillance. Numerous studies have shown the role of tumor autoantibodies as biomarkers for ovarian cancer diagnosis and its recurrence. These autoantibodies to Tumor Associated Antigens (TAAs) arise due to the generation of humoral immune response before evidence of clinical symptoms in cancer patients. Previously we showed that a 3 biomarker panel predicted ovarian cancer recurrence at a median lead time of 9.07 months with 94.7% sensitivity, 86.7% specificity, and 93.3% accuracy, in a cohort of ovarian cancer patients where normalization of CA125 had occurred after the surgery and completion of chemotherapy. One of those biomarkers was a peptide epitope from a known para neoplastic antigen, HARS. Para neoplastic antigens can elicit a humoral immune response in cancer patients as these antigens are expressed in the cells of nervous system and tumor

Author(s):

Michael Andrew

Abstract | Full-Text | PDF

Share this